A serum-free Vero production platform for a chimeric virus vaccine candidate

Cytotechnology

Volumn 51, Issue 3, 2006, Pages 183-192

  Yuk, Inn H ^a,b   Lin, Gina B ^a   Ju, Hui ^a   Sifi, Inesse ^a   Lam, Yvonne ^a   Cortez, Armida ^a   Liebertz, Danny ^a   Berry, J Michael ^a   Schwartz, Richard M ^a  

^a MedImmune   (United States)

^b GENENTECH INC   (United States)

Author keywords

Bioreactors; Microcarriers; Roller bottles; Serum free; Vero cultures; Virus production

Indexed keywords

VIRUS VACCINE;

ACUTE RESPIRATORY TRACT DISEASE; ANIMAL CELL; ARTICLE; BIOREACTOR; CELL CULTURE; CELL CULTURE EQUIPMENT; CELL PROLIFERATION; CONTROLLED STUDY; CULTURE MEDIUM; NONHUMAN; PARAINFLUENZA VIRUS 3; PARAMETER; REPRODUCIBILITY; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; ROLLER BOTTLE; SCALE UP; SERUM; SPINNER FLASK; VACCINATION; VERO CELL; VIRUS CULTURE; VIRUS TITRATION;

HUMAN PARAINFLUENZA VIRUS 3; RESPIRATORY SYNCYTIAL VIRUS;

EID: 33845291880     PISSN: 09209069     EISSN: 15730778     Source Type: Journal    
DOI: 10.1007/s10616-006-9030-7     Document Type: Article

References (32)

1. Asher DM (1999) The transmissible spongiform encephalopathy agents: concerns and responses of United States regulatory agencies in maintaining the safety of biologics. Dev Biol Stand 100:103-118
2. Bender FC, Whitbeck JC, de Leon MP, Lou H, Eisenbery RJ, Cohen GH (2003) Specific association of glycoprotein B with lipid rafts during Herpes Simplex Virus entry. J Virol 77:9542-9552
3. Berry JM, Barnabe N, Coombe KM, Butler M (1999) Production of reovirus type-1 and type-3 from Vero cells grown on solid and macroporous microcarriers. Biotechnol Bioeng 62:12-19
4. Brown G, Rixon HWM, Steel J, McDonald TP, Pitt AR, Graham S, Sugrue RJ (2005) Evidence for an association between heat shock protein 70 and the respiratory syncytial virus polymerase complex within lipid-raft membranes during virus infection. Virology 338:69-80
5. Castle P, Robertson JS (1999) Animal sera, animal sera derivatives and substitutes used in the manufacture of pharmaceuticals: viral safety and regulatory aspects. Dev Biol Stand 99:191-196
6. Erickson GA, Landgraf JG, Wessman SJ, Koski TA, Moss LM (1989) Detection and elimination of adventitious agents in continuous cell lines. Dev Biol Stand 70:59-66
7. Feller JA, Smallwood S, Skiadopoulos MH, Murphy BR, Moyer SA (2000) Comparison of identical temperature-sensitive mutations in the L polymerase proteins of Sendai and Parainfluenza 3 viruses. Virology 275:190-201
8. Galbraith DN (2002) Transmissible spongiform encephalopathies and tissue cell culture. Cytotechnology 39:117-124
9. Hall CD (2001) Respiratory syncytial virus and parainfluenza virus. N Engl J Med 344:1917-1927
10. Haller AA, Miller T, Mitiku M, Coelingh K (2000) Expression of the surface glycoproteins of human parainfluenza virus type 3 by bovine parainfluenza virus type 3, a novel attenuated virus vaccine vector. J Virol 74:11626-11635
11. Haller AA, Mitiku M, MacPhail M (2003) Bovine parainfluenza virus type 3 (PIV3) expressing the respiratory syncytial virus (RSV) attachment and fusion proteins protects hamsters from challenge with human PIV3 and PSV. J Gen Virol 84:2153-2162
12. Henry O, Dormond E, Perrier M, Kamen A (2004) Insights into adenoviral vector production kinetics in acoustic filter-based perfusion cultures. Biotechnol Bioeng 86:765-774
13. Hu WS, Wang DIC (1987) Selection of microcarrier diameter for the cultivation of mammalian cells on microcarriers. Biotechnol Bioeng 30:548-557
14. Kaptein LCM, Greijer AE, Valerio D, van Beusechem VW (1997) Optimized conditions for the production of recombinant amphotropic retroviral vector preparations. Gene Ther 4:172-176
15. Kamen A, Henry O (2004) Development and optimization of an adenovirus production process. J Gene Med 6:S184-S192
16. Kotani H, Newton PB, Zhang S, Chiang YL, Otto E, Weaver L, Blaese RM, Anderson WF, McGarrity GJ (1994) Improved methods of retroviral vector transduction and production for gene therapy. Hum Gene Ther 5:19-28
17. Lee SG, Kim S, Robbins PD, Kim BG (1996) Optimization of environmental factors for the production and handling of recombinant retrovirus. Appl Microbiol Biotechnol 45:477-483
18. Litwin J (1992) The growth of Vero cells in suspension as cell-aggregates in serum-free media. Cytotechnology 10:169-174
19. Montagnon BJ (1989) Polio and rabies vaccines produced in continuous cell lines: a reality for Vero cell line. Dev Biol Stand 70:27-47
20. Montagnon BJ, Vincent-Falquet JC (1998) Experience with the Vero cell line. Dev Biol Stand 93:119-123
21. Nadeau I, Gilbert PA, Jacob D, Perrier M, Kamen A (2002) Low-protein medium affects the 293SF central metabolism during growth and infection with adenovirus. Biotechnol Bioeng 77:91-104
22. Nadeau I, Kamen A (2003) Production of adenovirus vector for gene therapy. Biotechnol Adv 20:475-489
23. Skiadopoulos MH, Surman S, Tatem JM, Paschalis M, Wu SL, Udem SA, Durbin P, Collins PL, Murphy BR (1999) Identification of mutations contributing to the temperature-sensitive, cold-adapted, and attenuation phenotypes of the live-attenuated, cold-passaged 45 (cp45) human parainfluenza virus 3 candidate vaccine. J Virol 73:1374-1381
24. Tang RS, Schickli JH, MacPhail M, Fernandes F, Bicha L, Spaete J, Fouchier RAM, Osterhaus ADME, Spaete R, Haller AA (2003) Effects of human metapneumovirus and respiratory syncytial virus antigen insertion in two 3′ proximal genome positions of bovine/human parainfluenza virus type 3 on virus replication and immunogenicity. J Virol 77:10819-10828
25. Tang RS, MacPhail M, Schickli JH, Kaur J, Robinson CL, Lawlor HA, Guzzetta JM, Spaete RR, Haller AA (2004) Parainfluenza virus type 3 expressing the native or soluble fusion (F) protein of respiratory syncytial virus (RSV) confers protection from RSV infection in African green monkeys. J Virol 78:11198-11207
26. Vincent-Falquet JC, Peyron L, Souvras M, Moulin JC, Tektoff J, Patet J (1989) Qualification of working cell banks for the Vero cell line to produce licensed human vaccines. Dev Biol Stand 70:153-156
27. Williams GM, Gunn JM (1974) Long-term cell culture of adult rat liver epithelial cells. Exp Cell Res 89:139-142
28. World Health Organization (1987a) Requirements for continuous cell lines used for biological substances. WHO Tech Rep Ser 745:99-115
29. World Health Organization (1987b) Requirements for rabies vaccine (inactivated) for human use produced in continuous cell lines. WHO Tech Rep Ser 760:167-189
30. Wu SC, Liu CC, Lian WC (2004) Optimization of microcarrier cell culture process for the inactivated enterovirus type 71 vaccine development. Vaccine 22:3858-3864
31. Yokomizo AY, Antoniazzi MM, Galdino PL, Azambunja N Jr, Jorge SAC, Pereira CA (2004) Rabies virus production in high Vero cell density cultures on macroporous microcarriers. Biotechnol Bioeng 85:506-515
32. Yuk IH, Olsen MM, Geyer S, Forestell SP (2004) Perfusion cultures of human tumor cells: a scalable production platform for oncolytic adenoviral vectors. Biotechnol Bioeng 86:637-642